Merck KGaA v. Integra Lifesciences I, Ltd.
Headline: Court expands patent safe-harbor for drug research, allowing pharmaceutical companies and labs to use patented compounds in preclinical testing when tied to FDA approval submissions.
Holding: The use of patented compounds in preclinical studies is protected under §271(e)(1) if there is a reasonable basis to believe the tests could produce information relevant to FDA approval submissions.
- Allows drug companies to test patented compounds during early development.
- Protects preclinical studies reasonably tied to FDA approval information.
- Does not shield unrelated basic research lacking a reasonable tie to FDA filings.
Summary
Background
A pharmaceutical company (Merck) funded university research at Scripps led by Dr. David Cheresh to test RGD peptides, a molecule class linked to blocking blood vessel growth. Patent holders (Integra and the Burnham Institute) sued, saying Merck supplied patented peptides and induced others to infringe. A jury found infringement and awarded damages; lower courts disagreed about whether the statutory exemption applied to preclinical testing.
Reasoning
The Court addressed whether a federal patent law exemption (§271(e)(1)) protects use of patented compounds in preclinical studies that are not themselves submitted to the FDA. The Justices read the statute to cover all uses reasonably related to developing information for FDA submissions. The opinion explains that the FDA wants preclinical information about safety, efficacy, mechanism, and other drug qualities, so many in vitro and animal studies can be relevant. The Court rejected narrowing the exemption to only research for generic drugs or only experiments actually included in an FDA filing.
Real world impact
The ruling means drug companies and research labs have breathing room to test patented compounds during early drug development when they reasonably expect the tests could produce information useful for FDA approval. It does not protect unrelated basic research that lacks a reasonable tie to FDA submissions. The Court vacated the Federal Circuit’s judgment and sent the case back so the trial evidence can be reviewed under this legal standard.
Dissents or concurrances
The Supreme Court was unanimous, though the Federal Circuit earlier issued a divided ruling with a dissent arguing for broader protection of the trials.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?